Enobosarm

Phase 2Small molecule

VVeru Inc.

Enobosarm is one of 11 small molecule programs targeting Obesity & Overweight. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obesity & OverweightActive, not recruiting

Obesity & OverweightPhase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Obesity & Overweight

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

1 2

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

1 3

Ozempic

Novo Nordisk

Phase 2

2 4

Crestor

AstraZeneca

Preclinical

1 5

Semagludtide

Novo Nordisk

Phase 2

1 6

LUM-201

LLumos Pharma

Phase 2

1 7

Enobosarm

VVeru Inc.

Phase 2

1 8

Spermidine

MMedical University of Graz

Preclinical

1 9

Incretin-Based Treatment

JJohns Hopkins University

Preclinical

1 10

GLP-1 Receptor Agonist Therapy

GGazi University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Obesity & Overweight

NCT07446998

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated·VVeru Inc.·Phase 3·NCT04869943·52 enrolled

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Completed·—·Phase 2·NCT02971761·18 enrolled

Menopausal Women1 trial

Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density

Completed·UUnknown Sponsor·Phase 1·NCT03264651·9 enrolled

Chronic1 trial

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

Completed·VVeru Inc.·Phase 2·NCT06282458·168 enrolled

Obesity & Overweight1 trial

PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm in Patients Treated With Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, for Weight Reduction

Active, not recruiting·VVeru Inc.·Phase 2·NCT07446998·239 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Enobosarm. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enobosarm compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enobosarm. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Veru Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVeru Inc.

Enobosarm

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Breast Cancer2 trials

Menopausal Women1 trial

Chronic1 trial

Obesity & Overweight1 trial

References

Drug Info

Quick Facts

Related News